

Publikationsliste

1. Originalarbeiten

1. Serra EG, Schwerd T, Moutsianas L, Cavounidis A, Fachal L, Pandey S, Kammermeier J, Croft NM, Posovszky C, Rodrigues A, Russell RK, Barakat F, Auth MKH, Heuschkel R, Zilbauer M, Fyderek K, Braegger C, Travis SP, Satsangi J, Parkes M, Thapar N, Ferry H, Matte JC, Gilmour KC, Wedrychowicz A, Sullivan P, Moore C, Sambrook J, Ouwehand W, Roberts D, Danesh J, Baeumler TA, Fulga TA, Karaminejadranjbar M, Ahmed A, Wilson R, Barrett JC, Elkadri A, Griffiths AM; COLORS in IBD group investigators; Oxford IBD cohort study investigators; INTERVAL Study; **Swiss IBD cohort investigators**; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, Snapper SB, Shah N, Muise AM, Wilson DC, Uhlig HH, Anderson CA.
Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.
Nat Commun. 2020 Feb 21;11(1):995. doi: 10.1038/s41467-019-14275-y
Impact Factor : 11.8
Citations : N/A
2. Sabev M, Blümel S, Lang S, Gottier C, Weber A, Mertens J, Müllhaupt B, **Scharl M**, Spalinger MR
Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients.
Digestion. 2020 Feb 19;19:1-9. doi: 10.1159/000505645
Impact Factor: 3.0
Citations: N/A
3. Grob L, Blümel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, **Scharl M**
Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study.
Therap Adv Gastroenterol. 2020 Jan 24;13:1756284819895217. doi: 10.1177/1756284819895217
Impact Factor: 4.1
Citations: 0
4. Niechcial A, Butter M, Manz S, Obialo N, Bähler K, van der Lely L, Lang S, Gottier C, McCole DF, **Scharl M**, Spalinger MR.
Presence of PTPN2 SNP rs1893217 Enhances the Anti-inflammatory Effect of Spermidine.
Inflamm Bowel Dis. 2020 Feb 7. pii: iza013. doi: 10.1093/ibd/iza013
Impact Factor: 4.0
Citations: N/A
5. Maeyashiki C, Melhem H, Hering L, Baebler K, Cosin-Roger J, Schefer F, Weder B, Hausmann M, **Scharl M**, Rogler G, de Vallière C, Ruiz PA.
Activation of pH-Sensing Receptor OGR1 (GPR68) Induces ER Stress Via the IRE1 α /JNK Pathway in an Intestinal Epithelial Cell Model.
Sci Rep. 2020 Jan 29;10(1):1438. doi: 10.1038/s41598-020-57657-9.
Impact Factor: 4.0
Citations: 0

6. Cernoch PS, Fournier N, Zeitz J, **Scharl M**, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group.
Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study.
Dig Dis Sci. 2019 Dec 3. doi: 10.1007/s10620-019-05978-9.
Impact Factor: 2.9
Citations: 0
7. Spalinger MR, Schwarzfischer M, Hering L, Shawki A, Sayoc A, Santos A, Gottier C, Lang S, Bähler K, Geirnaert A, Lacroix C, Leventhal GE, Dai X, Rawlings D, Chan AA, Rogler G, McCole DF, **Scharl M**
Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis.
Mucosal Immunol. 2019 Nov;12(6):1336-1347. doi: 10.1038/s41385-019-0201-1. Epub 2019 Sep 9.
Impact Factor: 7.3
Citations: 0
8. Montalban-Arques A, **Scharl M**
Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy.
EBioMedicine. 2019 Oct;48:648-655. doi: 10.1016/j.ebiom.2019.09.050. Epub 2019 Oct 17. Review.
Impact Factor: 6.6
Citations: 0
9. van der Lely L, Häfliger J, Montalban-Arques A, Bähler K, Schwarzfischer M, Sabev M, Gottier C, Lang S, **Scharl M**, Spalinger MR.
Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells.
Inflamm Intest Dis. 2019 Oct;4(4):161-173. doi: 10.1159/000502861. Epub 2019 Sep 17
Impact Factor: N/A
Citations: N/A
10. Frei R, Fournier N, Zeitz J, **Scharl M**, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L.
Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study.
J Crohns Colitis. 2019 Sep 27;13(10):1292-1301. doi: 10.1093/ecco-jcc/ijz057
Impact Factor: 7.8
Citations: 1
11. Humbel F, Rieder JH, Franc Y, Juillerat P, **Scharl M**, Misselwitz B, Schreiner P, Begré S, Rogler G, von Känel R, Yilmaz B, Biedermann L; Swiss IBD Cohort Study Group
Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission
Clin Gastroenterol Hepatol. 2019 Sep 20. pii: S1542-3565(19)31028-6
Impact factor: 7.95
Citations: N/A
12. Raselli T, Wyss A, Gonzalez Alvarado MN, Weder B, Mamie C, Spalinger MR, Van Haaften WT, Dijkstra G, Sailer AW, Imenez Silva PH, Wagner CA, Tosevski V, Leibl S, **Scharl M**, Rogler G, Hausmann M, Misselwitz B.
The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis
J Crohns Colitis. 2019 Sep 19;13(9):1186-1200
Impact Factor: 7.82
Citations: N/A

13. Spalinger MR, Schwarzfischer M, Hering L, Shawki A, Sayoc A, Santos A, Gottier C, Lang S, Bähler K, Geirnaert A, Lacroix C, Leventhal GE, Dai X, Rawlings D, Chan AA, Rogler G, McCole DF, **Scharl M**
Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis
Mucosal Immunol. 2019 Sep 9
Impact Factor: 7.35
Citations: N/A
14. Biedermann L, Renz L, Fournier N, Rossel JB, Butter M, Bluemel S, Vavricka SR, Rogler G, **Scharl M**.
Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
Therap Adv Gastroenterol. 2019 Aug 13;12:1756284819865142
Impact Factor: 4.16
Citations: 0
15. Greuter T, Vavricka SR, **Scharl M**.
Response to Al Sulais et al.
Am J Gastroenterol. 2019 Aug;114(8):1346-1347.
Impact Factor: 10.24
Citations: 0
16. King SJ, Bunz M, Chappell A, **Scharl M**, Docherty M, Jung B, Lytle C, McCole DF.
AMPK mediates inhibition of electrolyte transport and NKCC1 activity by reactive oxygen species.
Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G171-G181.
Impact Factor: 3.72
Citations: 0
17. Bengs S, Becker E, Busenhardt P, Spalinger MR, Raselli T, Kasper S, Lang S, Atrott K, Mamie C, Vavricka SR, von Boehmer L, Knuth A, Tuomisto A, Mäkinen MJ, Hruz P, Turina M, Rickenbacher A, Petrowsky H, Weber A, Frei P, Halama M, Jenkins G, Sheppard D, Croner RS, Christoph J, Britzen-Laurent N, Naschberger E, Schellerer V, Stürzl M, Fried M, Rogler G, **Scharl M**.
 $\beta 6$ -integrin serves as a novel serum tumor marker for colorectal carcinoma
Int J Cancer. 2019 Aug 1;145(3):678-685.
Impact Factor: 4.98
Citations: 0
18. Ortiz-Masià D, Salvador P, Macias-Ceja DC, Gisbert-Ferrándiz L, Esplugues JV, Manyé J, Alós R, Navarro-Vicente F, Mamie C, **Scharl M**, Cosin-Roger J, Calatayud S, Barrachina MD.
WNT2b activates epithelial-mesenchymal transition through FZD4: relevance in penetrating Crohn's disease
J Crohns Colitis. 2019 Jul 30. pii: jjz134.
Impact Factor: 7.82
Citations: N/A
19. Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, **Scharl M**, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R.
Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease
Inflamm Bowel Dis. 2019 Jul 17;25(8):1357-1366.
Impact Factor: 4.0
Citations: 0

20. Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, **Scharl M**, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B.
Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis
J Lipid Res. 2019 Jul;60(7):1270-1283.
Impact Factor: 4.74
Citations: 0
21. Schreiner P, Yilmaz B, Rossel JB, Franc Y, Misselwitz B, **Scharl M**, Zeitz J, Frei P, Greuter T, Vavricka SR, Pittet V, Siebenhüner A, Juillerat P, von Känel R, Macpherson AJ, Rogler G, Biedermann L; Swiss IBD Cohort Study Group.
Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease
United European Gastroenterol J. 2019 Jul;7(6):767-781.
Impact Factor: 3.45
Citations: 0
22. Poeker SA, Lacroix C, de Wouters T, Spalinger MR, **Scharl M**, Geirnaert A.
Stepwise Development of an in vitro Continuous Fermentation Model for the Murine Caecal Microbiota
Front Microbiol. 2019 May 29;10:1166.
Impact Factor: 4.25
Citations: 0
23. Spalinger MR, Atrott K, Baebler K, Schwarzfischer M, Melhem H, Peres DR, Lalazar G, Rogler G, **Scharl M**, Frey-Wagner I.
Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis
J Crohns Colitis. 2019 May 27;13(6):785-797.
Impact Factor: 7.82
Citations: 0
24. Bruckner RS, Nissim-Eliraz E, Marsiano N, Nir E, Shemesh H, Leutenegger M, Gottier C, Lang S, Spalinger MR, Leibl S, Rogler G, Yagel S, **Scharl M**, Shpigel NY.
Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas
J Crohns Colitis. 2019 May 27;13(6):798-806.
Impact Factor: 7.82
Citations: 0
25. Spalinger MR, Schmidt TS, Schwarzfischer M, Hering L, Atrott K, Lang S, Gottier C, Geirnaert A, Lacroix C, Dai X, Rawlings DJ, Chan AC, von Mering C, Rogler G, **Scharl M**.
Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner
J Clin Invest. 2019 May 20;129(6):2527-2541.
Impact Factor: 12.28
Citations: 0
26. Ulugöl S, Hering L, Manzini R, Montalban Arques A, Gottier C, Lang S, **Scharl M**, Spalinger MR.
Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23
Inflamm Intest Dis. 2019 May;4(1):14-26.
Impact Factor: N/A
Citations: N/A

27. Wyss A, Raselli T, Perkins N, Ruiz F, Schmelczner G, Klinke G, Moncsek A, Roth R, Spalinger MR, Hering L, Atrott K, Lang S, Frey-Wagner I, Mertens JC, **Scharl M**, Sailer AW, Pabst O, Hersberger M, Pot C, Rogler G, Misselwitz B.
The EB12-oxysterol axis promotes the development of intestinal lymphoid structures and colitis
Mucosal Immunol. 2019 May;12(3):733-745.
Impact Factor: 7.35
Citations: 4
28. Hiller A, Biedermann L, Fournier N, Butter M, Vavricka SR, Ciurea A, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group.
The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort
PLoS One. 2019 Apr 30;14(4):e0211554.
Impact Factor: 2.77
Citations: 0
29. Bon L, Scharl S, Vavricka S, Rogler G, Fournier N, Pittet V, **Scharl M**, Greuter T, Schreiner P, Frei P, Misselwitz B, Biedermann L, Zeitz J; Swiss IBD Cohort Study Group.
Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study
PLoS One. 2019 Apr 25;14(4):e0215738
Impact Factor: 2.77
Citations: 0
30. Kochar B, Herfarth N, Mamie C, Navarini AA, **Scharl M**, Herfarth HH.
Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Clin Gastroenterol Hepatol. 2019 Apr;17(5):991-993.
Impact Factor: 7.95
Citations: 4
31. Frei R, Fournier N, Zeitz J, **Scharl M**, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group.
Early Initiation of Anti-Tnf is Associated with Favourable Long-Term Outcome in Crohn's Disease: 10-Year-Follow-Up Data from the Swiss IBD Cohort Study.
J Crohns Colitis. 2019 Mar 7. pii: jjz057.
Impact Factor: 7.82
Citations: N/A
32. Mürner CM, Stenner-Liewen F, Seifert B, Mueller NJ, Schmidt A, Renner C, Schanz U, Knuth A, Manz MG, **Scharl M**, Gerber B, Samaras P.
Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation.
Leuk Lymphoma. 2019 Mar;60(3):685-695.
Impact Factor: 2.67
Citations: 0
33. Bardenbacher M, Ruder B, Britzen-Laurent N, Schmid B, Waldner M, Naschberger E, **Scharl M**, Müller W, Günther C, Becker C, Stürzl M, Tripal P.
Permeability analyses and three dimensional imaging of interferon gamma-induced barrier disintegration in intestinal organoids
Stem Cell Res. 2019 Mar;35:101383.
Impact Factor: 3.92
Citations: 0

34. Tcymbarevich I, Richards SM, Russo G, Kühn-Georgijevic J, Cosin-Roger J, Baebler K, Lang S, Bengs S, Atrott K, Bettoni C, Gruber S, Frey-Wagner I, **Scharl M**, Misselwitz B, Wagner CA, Seuwen K, Rogler G, Ruiz PA, Spalinger M, de Vallière C.
Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease
J Crohns Colitis. 2019 Feb 1;13(2):245-258.
Impact Factor: 7.82
Citations: 0
35. Roth N, Biedermann L, Fournier N, Butter M, Vavricka SR, Navarini AA, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group.
Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
PLoS One. 2019 Jan 25;14(1):e0210436.
Impact Factor: 2.77
Citations: 0
36. Tcymbarevich IV, Eloranta JJ, Rossel JB, Obialo N, Spalinger M, Cosin-Roger J, Lang S, Kullak-Ublick GA, Wagner CA, **Scharl M**, Seuwen K, Ruiz PA, Rogler G, de Vallière C, Misselwitz B; Swiss IBD Cohort Study Group.
The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation.
BMC Gastroenterol. 2019 Jan 7;19(1):2.
Impact Factor: 2.25
Citations: 0
37. Scharl S, Barthel C, Rossel JB, Biedermann L, Misselwitz B, Schoepfer AM, Straumann A, Vavricka SR, Rogler G, **Scharl M**, Greuter T.
Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study.
Am J Gastroenterol. 2019 Jan;114(1):116-126.
Impact Factor: 10.24
Citations: 1
38. Simmen S, Cosin-Roger J, Melhem H, Maliachovas N, Maane M, Baebler K, Weder B, Maeyashiki C, Spanaus K, **Scharl M**, de Vallière C, Zeitz J, Vavricka SR, Hausmann M, Rogler G, Ruiz PA.
Iron Prevents Hypoxia-Associated Inflammation Through the Regulation of Nuclear Factor- κ B in the Intestinal Epithelium.
Cell Mol Gastroenterol Hepatol. 2019;7(2):339-355.
Impact Factor: N/A
Citations: 1
39. **Scharl M.**
Perianal fistulas in CED: from mouse model to clinic
Ther Umsch. 2019 Jan;75(5):287-294
Impact Factor: N/A
Citations: 0
40. Greuter T, Piller A, Fournier N, Safroneeva E, Straumann A, Biedermann L, Godat S, Nydegger A, **Scharl M**, Rogler G, Vavricka SR, Schoepfer AM; Swiss IBD Cohort Study Group.
Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course.
J Crohns Colitis. 2018 Nov 28;12(12):1399-1409.

Impact Factor: 7.82

Citations: 2

41. Wotzka SY, Kreuzer M, Maier L, Zünd M, Schlumberger M, Nguyen B, Fox M, Pohl D, Heinrich H, Rogler G, Biedermann L, **Scharl M**, Sunagawa S, Hardt WD, Misselwitz B.
Microbiota stability in healthy individuals after single-dose lactulose challenge-A randomized controlled study
PLoS One. 2018 Oct 25;13(10):e0206214.
Impact Factor: 2.77
Citations: 2
42. Wawrzyniak M, **Scharl M**.
Genetics and epigenetics of inflammatory bowel disease
Swiss Med Wkly. 2018 Sep 23;148:w14671.
Impact Factor: 1.82
Citations: 1
43. Mürner CM, Stenner-Liewen F, Seifert B, Mueller NJ, Schmidt A, Renner C, Schanz U, Knuth A, Manz MG, **Scharl M**, Gerber B, Samaras P.
Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation.
Leuk Lymphoma. 2018 Aug 21:1-11.
Impact factor: 2.75
Citations: 56
44. Vavricka Sr, Heinrich H, Buetikofer S, Breitenmoser F, Burri E, Schneider-Ain X, Barman-Aksoezen J, Biedermann L, **Scharl M**, Zeitz J, Rogler G, Misselwitz B, Sauter M
The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding
United European Gastroenterology Journal, Volume 6, Issue 7, 1 August 2018, Pages 1007-1014
Impact factor: N/A
Citations: 0
45. Yilmaz B, Spalinger MR, Biedermann L, Franc Y, Fournier N, Rossel JB, Juillerat P, Rogler G, Macpherson AJ, **Scharl M**.
The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients.
PLoS One. 2018 Jul 2;13(7):e0199664.
Impact factor: 2.80
Citations: 0
46. Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group .
The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort.
Inflamm Bowel Dis. 2018 Jul 12;24(8):1768-1779
Impact factor: 4.52
Citations: 0
47. Parragi L, Fournier N, Zeitz J, **Scharl M**, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group
Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study.
J Crohns Colitis. 2018 Jun 28;12(7):811-818.

Impact factor: 5.81

Citations: 0

48. Herzog D, Fournier N, Buehr P, Rueger V, Koller R, Heyland K, Nydegger A, Spalinger J, Schibli S, Petit LM, Braegger CP; **Swiss IBD Cohort Study Group**. *Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications.* Eur J Gastroenterol Hepatol. 2018 Jun;30(6):598-607
Impact factor: 1.96
Citations: 1
49. Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; **Swiss IBD Cohort Study Group**. *Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.* Eur J Gastroenterol Hepatol. 2018 Jun;30(6):612-620
Impact factor: 1.96
Citations: 0
50. Burisch J, Gisbert JP, Siegmund B, Bettenworth D, Thomsen SB, Cleynen I, Cremer A, Ding NJS, Furfaro F, Galanopoulos M, Grunert PC, Hanzel J, Ivanovski TK, Krustins E, Noor N, O'Morain N, Rodríguez-Lago I, **Scharl M**, Tua J, Uzzan M, Ali Yassin N, Baert F, Langholz E. *Validation of the 'United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease.* J Crohns Colitis. 2018 Apr 27;12(5):532-537
Impact factor: 5.81
Citations: 0
51. Nagy N, Marsiano N, Bruckner RS, **Scharl M**, Gutnick MJ, Yagel S, Arciero E, Goldstein AM, Shpigel NY. *Xenotransplantation of human intestine into mouse abdomen or subcutaneous tissue: Novel platforms for the study of the human enteric nervous system.* Neurogastroenterol Motil. 2018 Mar;30(3)
Impact factor: 3.61
Citations: 0
52. Greuter T, Franc Y, Kaelin M, Schoepfer AM, Schreiner P, Zeitz J, **Scharl M**, Misselwitz B, Straumann A, Vavricka SR, Rogler G, von Känel R, Biedermann L. *Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients.* Therap Adv Gastroenterol. 2018 Feb 19;11:1756283X18757715
Impact factor: 3.64
Citations: 0
53. Cosin-Roger J, Spalinger MR, Ruiz PA, Stanzel C, Terhalle A, Wolfram L, Melhem H, Atrott K, Lang S, Frey-Wagner I, Fried M, **Scharl M**, Hausmann M, Rogler G. *Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation.* PLoS One. 2018 Feb 15;13(2):e0193003
Impact factor: 2.80
Citations: 0

54. Spalinger MR, Manzini R, Hering L, Riggs JB, Gottier C, Lang S, Atrott K, Fettelschoss A, Olomski F, Kündig TM, Fried M, McCole DF, Rogler G, **Scharl M**.
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
Cell Rep. 2018 Feb 13;22(7):1835-1848
Impact factor: 8.28
Citations: 2
55. Vavricka SR, Galván JA, Dawson H, Soltermann A, Biedermann L, **Scharl M**, Schoepfer AM, Rogler G, Prinz Vavricka MB, Terracciano L, Navarini A, Zlobec I, Lugli A, Greuter T.
Expression Patterns of TNF α , MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
J Crohns Colitis. 2018 Feb 28;12(3):347-354.
Impact factor: 5.81
Citations: 0
56. Lang BM, Biedermann L, van Haaften WT, de Vallière C, Schuurmans M, Bègré S, Zeitz J, **Scharl M**, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B; Swiss IBD Cohort Study Group.
Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease.
Aliment Pharmacol Ther. 2018 Jan;47(1):55-66
Impact factor: 7.28
Citations: 3
57. Vavricka SR, Stelzer T, Lattmann J, Stotz M, Lehmann R, Zeitz J, **Scharl M**, Misselwitz B, Pohl D, Fried M, Tutuian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L, Greuter T.
Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients.
J Clin Gastroenterol. 2018 Jan;52(1):25-29
Impact factor: 3.32
Citations: 1
58. Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, Spalinger M, Battegay E, Zimmerli L, Vavricka SR, Rogler G, **Scharl M**, Misselwitz B.
Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases.
PLoS One. 2017 Oct 12;12(10):e0185193
Impact factor: 2.80
Citations: 1
59. Spalinger MR, Lang S, Gottier C, Dai X, Rawlings DJ, Chan AC, Rogler G, **Scharl M**.
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
Autophagy. 2017 Sep 2;13(9):1590-1601
Impact factor: 8.59
Citations: 2
60. Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, **Scharl M**, Rogler G, Safroneeva E, Ali RAR, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR; Swiss IBD Cohort Study Group.
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):200-206
Impact factor: 2.79
Citations: 10

61. Ruiz PA, Morón B, Becker HM, Lang S, Atrott K, Spalinger MR, **Scharl M**, Wojtal KA, Fischbeck-Terhalle A, Frey-Wagner I, Hausmann M, Kraemer T, Rogler G.
Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome.
Gut. 2017 Jul;66(7):1216-1224
Impact factor: 16.65
Citations: 24
62. Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, **Scharl M**, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group.
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
Inflamm Bowel Dis. 2017 Jul;23(7):1174-1181
Impact factor: 4.52
Citations: 7
63. Schüle S, Rossel JB, Frey D, Biedermann L, **Scharl M**, Zeitz J, Freitas-Queiroz N, Kuntzen T, Greuter T, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study.
Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study.
Medicine (Baltimore). 2017 Jun;96(22):e6788
Impact factor: 1.80
Citations: 2
64. Vavricka SR, Spasojevic M, Rogler G, Schoepfer AM, Seibold F, Borovicka J, Frei P, Zeitz J, Greuter T, Manser C, **Scharl M**, Misselwitz B, Straumann A, Michetti P, Biedermann L; Swiss IBDnet.
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
Dig Dis. 2017;35(5):423-432
Impact factor: 1.77
Citations: 1
65. Zeitz J, Fournier N, Labenz C, Biedermann L, Frei P, Misselwitz B, Scharl S, Vavricka SR, Sulz MC, Fried M, Rogler G, **Scharl M**.
Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort.
Inflamm Intest Dis. 2017 Apr;1(4):172-181
Impact factor: N/A
Citations: N/A
66. Greuter T, Schmidlin S, Lattmann J, Stotz M, Lehmann R, Zeitz J, **Scharl M**, Misselwitz B, Pohl D, Fried M, Tutian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L, Vavricka SR
The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity
Dig Liver Dis. 2017 Mar, 49(3):268-272
Impact factor: 3.06
Citations: 0
67. Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, Frei P, Vavricka SR, Fried M, Rogler G, **Scharl M**.
Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?
Eur J Gastroenterol Hepatol. 2017 Mar;29(3):322-330
Impact factor: 1.96
Citations: 3

68. Pittet V, Vaucher C, Froehlich F, Burnand B, Michetti P, Maillard MH; **Swiss IBD Cohort Study Group**. *Patient self-reported concerns in inflammatory bowel diseases: A gender-specific subjective quality-of-life indicator*. PLoS One. 2017 Feb 10;12(2):e0171864.
Impact factor: 2.80
Citations: 2
69. Vavricka S, Ruiz PA, Scharl S, Biedermann L, **Scharl M**, de Vallière C, Lundby C, Wenger RH, Held L, Merz TM, Gassmann M, Lutz T, Kunz A, Bron D, Fontana A, Strauss L, Weber A, Fried M, Rogler G, Zeitz J. *Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study*. BMJ Open. 2017 Jan 5;7(1):e013477
Impact factor: 2.36
Citations: 1
70. Bontà J, Zeitz J, Frei P, Biedermann L, Sulz MC, Vavricka SR, Scharl S, Fried M, Rogler G, **Scharl M**. *Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience*. Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1329-34.
Impact factor: 1.96
Citations: 4
71. Schüle S, Rossel JB, Frey D, Biedermann L, **Scharl M**, Zeitz J, Freitas-Queiroz N, Pittet V, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. *Prediction of low bone mineral density in patients with inflammatory bowel diseases*. United European Gastroenterol J. 2016 Oct;4(5):669-676
Impact factor: 3.67
Citations: 4
72. Vavricka SR, Vadasz N, Stotz M, Lehmann R, Studerus D, Greuter T, Frei P, Zeitz J, **Scharl M**, Misselwitz B, Pohl D, Fried M, Tutuiian R, Fasano A, Schoepfer AM, Rogler G, Biedermann L. *Celiac disease diagnosis still significantly delayed - Doctor's but not patients' delay responsive for the increased total delay in women*. Dig Liver Dis. 2016 Oct;48(10):1148-54.
Impact factor: 3.06
Citations: 7
73. Goffin L, Fagagnini S, Vicari A, Mamie C, Melhem H, Weder B, Lutz C, Lang S, **Scharl M**, Rogler G, Chvatchko Y, Hausmann M. *Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis*. Inflamm Bowel Dis. 2016 Sep;22(9):2041-57
Impact factor: 4.52
Citations: 16
74. Spalinger MR, Zeitz J, Biedermann L, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group. *Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort*. PLoS One. 2016 Jul 28;11(7):e0160215
Impact factor: 2.80
Citations: 2

75. Zeitz J, Ak M, Müller-Mottet S, Scharl S, Biedermann L, Fournier N, Frei P, Pittet V, **Scharl M**, Fried M, Rogler G, Vavricka S; Swiss IBD Cohort Study Group.
Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account.
PLoS One. 2016 Jun 22;11(6):e0156666.
Impact factor: 2.80
Citations: 8
76. Madanchi M, Zeitz J, Barthel C, Samaras P, Scharl S, Sulz MC, Biedermann L, Frei P, Vavricka SR, Rogler G, **Scharl M**.
Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience.
Digestion. 2016;94(1):1-8
Impact factor: 2.08
Citations: 5
77. Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Raselli T, Frey-Wagner I, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, **Scharl M**.
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
J Clin Invest. 2016 Mai;126(5):1783-800.
Impact factor: 12.78
Citations: 28
78. Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, **Scharl M**.
The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.
PLoS One. 2016 May 23;11(5):e0155218
Impact factor: 2.80
Citations: 7
79. Roth S, Spalinger MR, Gottier C, Biedermann L, Zeitz J, Lang S, Weber A, Rogler G, **Scharl M**.
Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis.
PLoS One. 2016 May 6;11(5):e0154817
Impact factor: 2.80
Citations: 9
80. Kasper SH, Spalinger MR, Leonardi I, Gerstgrasser A, Raselli T, Gottier C, Atrott K, Frey-Wagner I, Fischbeck-Terhalle A, Rogler G, **Scharl M**.
Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.
Digestion. 2016;93(4):249-59
Impact factor: 2.08
Citations: 3
81. Spalinger MR, Voegelin M, Biedermann L, Zeitz J, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, **Scharl M**; Swiss IBD Cohort Study Group.
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.
Digestion. 2016;93(3):182-92.
Impact factor: 2.08
Citations: 2

82. Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, **Scharl M**, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R.
Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease.
Am J Gastroenterol. 2016 Apr;111(4):529-40
Impact factor: 9.56
Citations: 6
83. Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; **Swiss IBD Cohort Study.**
Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?
J Crohns Colitis. 2016 Mar;10(3):269-76
Impact factor: 5.81
Citations: 3
84. Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, **Scharl M**, Aguzzi A, Oldrige DA, Maris JM, Rogler G.
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
PLoS One. 2016 Jan 28;11(1):e0147682.
Impact factor: 2.80
Citations: 11
85. Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J, Lang S, **Scharl M**, Rogler G.
Mutant HRAS as novel target for MEK and mTOR inhibitors.
Oncotarget. 2015 Dec 8;6(39):42183-96
Impact factor: 5.16
Citations: 9
86. Aradi B, Kato M, Filkova M, Karouzakis E, Klein K, **Scharl M**, Kolling C, Michel BA, Gay RE, Buzas EI, Gay S, Jünger A.
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of Interleukin-6 production in rheumatoid arthritis synovial fibroblasts.
Arthritis Rheumatol. 2015 Oct;67(10):2624-33
Impact factor: 6.91
Citations: 9
87. Barthel C, Wiegand S, Scharl S, **Scharl M**, Frei P, Vavricka SR, Fried M, Sulz MC, Wiegand N, Rogler G, Biedermann L.
Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey.
Nutr J. 2015 Aug 12;14:78
Impact factor: 3.21
Citations: 1
88. Spalinger MR, Kasper S, Chassard C, Raselli T, Frey-Wagner I, Gottier C, Lang S, Atrott K, Vavricka SR, Mair F, Becher B, Lacroix C, Fried M, Rogler G, **Scharl M.**
PTPN2 controls differentiation of CD4⁺ T cells and limits intestinal inflammation and intestinal dysbiosis.
Mucosal Immunol. 2015 Jul;8(4):918-29
Impact factor: 7.47
Citations: 19

89. de Vallière C, Wang Y, Eloranta JJ, Vidal S, Clay I, Spalinger MR, Tcymbarevich I, Terhalle A, Ludwig MG, Suply T, Fried M, Kullak-Ublick GA, Frey-Wagner I, **Scharl M**, Seuwen K, Wagner CA, Rogler G. *G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation*. *Inflamm Bowel Dis*. 2015 Jun;21(6):1269-81
Impact factor: 4.52
Citations: 18
90. **Scharl M**, Huber N, Lang S, Fürst A, Jehle E, Rogler G. *Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis*. *Clin Transl Med*. 2015 Feb 7;4:1
Impact factor: 5.93
Citations: 0
91. Kasper SH, Spalinger MR, Raselli T, **Scharl M**. *A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling*. *Digestion*. 2015;91(3):248-56.
Impact factor: 2.08
Citations: 1
92. Roth S, Spalinger MR, Müller I, Lang S, Rogler G, **Scharl M**. *Bilberry-derived anthocyanins prevent IFN- γ -induced pro-inflammatory signalling and cytokine secretion in human THP-1 monocytic cells*. *Digestion*. 2014;90(3):179-89
Impact factor: 2.08
Citations: 10
93. Biedermann L, Brülisauer K, Zeitz J, Frei P, **Scharl M**, Vavricka SR, Fried M, Loessner MJ, Rogler G, Schuppler M. *Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH*. *Inflamm Bowel Dis*. 2014 Sep;20(9):1496-501
Impact factor: 4.52
Citations: 40
94. Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P9, Pittet V; **Swiss IBD Cohort Study Group**. *Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis*. *J Crohns Colitis*. 2014 Aug;8(8):825-34
Impact factor: 5.81
Citations: 1
95. Gutiérrez A, **Scharl M**, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. *Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease*. *Gut*. 2014 Feb;63(2):272-80
Impact factor: 16.65
Citations: 30

96. Barthel C, Biedermann L, Frei P, Vavricka SR, Kündig T, Fried M, Rogler G, **Scharl M**.
Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.
Digestion. 2014;89(3):209-15
Impact factor: 2.08
Citations: 14
97. Becker HM, Apladas A, **Scharl M**, Fried M, Rogler G.
Probiotic Escherichia coli Nissle 1917 and commensal E. coli K12 differentially affect the inflammasome in intestinal epithelial cells.
Digestion. 2014;89(2):110-8
Impact factor: 2.08
Citations: 12
98. **Scharl M**, Frei P, Frei SM, Biedermann L, Weber A, Rogler G.
Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease.
Eur J Gastroenterol Hepatol. 2014 Jan;26(1):114-8
Impact factor: 1.96
Citations: 11
99. Vavricka SR, Manser CN, Hediger S, Vögelin M, **Scharl M**, Biedermann L, Rogler S, Seibold F, Sanderink R, Attin T, Schoepfer A, Fried M, Rogler G, Frei P.
Periodontitis and gingivitis in inflammatory bowel disease: a case-control study.
Inflamm Bowel Dis. 2013 Dec;19(13):2768-77
Impact factor: 4.52
Citations: 23
100. Frei SM, Pesch T, Lang S, Weber A, Jehle E, Vavricka SR, Fried M, Rogler G, **Scharl M**.
A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohn's disease-associated fistulae.
Inflamm Bowel Dis. 2013 Dec;19(13):2878-87.
Impact factor: 4.52
Citations: 8
101. Frei SM, Hemsley C, Pesch T, Lang S, Weber A, Jehle E, Rühl A, Fried M, Rogler G, **Scharl M**.
The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae.
PLoS One. 2013 Nov 8;8(11):e78882
Impact factor: 2.80
Citations: 7
102. Morón B, Spalinger M, Kasper S, Atrott K, Frey-Wagner I, Fried M, McCole DF, Rogler G, **Scharl M**.
Activation of protein tyrosine phosphatase non-receptor type 2 by spermidine exerts anti-inflammatory effects in human THP-1 monocytes and in a mouse model of acute colitis.
PLoS One. 2013 Sep 9;8(9):e73703.
Impact factor: 2.80
Citations: 14

103. Spalinger MR, Lang S, Vavricka SR, Fried M, Rogler G, **Scharl M**.
Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy.
PLoS One. 2013 Aug 26;8(8):e72384
Impact factor: 2.80
Citations: 15
104. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; **Swiss Inflammatory Bowel Disease Cohort Study Group**.
Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease.
Digestion. 2013;87(3):212-21
Impact factor: 2.08
Citations: 16
105. Wojtal KA, Wolfram L, Frey-Wagner I, Lang S, **Scharl M**, Vavricka SR, Rogler G.
The effects of vitamin A on cells of innate immunity in vitro.
Toxicol In Vitro. 2013 Aug;27(5):1525-32
Impact factor: 2.86
Citations: 12
106. Biedermann L, Zeitz J, Mwinyi J, Sutter-Minder E, Rehman A, Ott SJ, Steurer-Stey C, Frei A, Frei P, **Scharl M**, Loessner MJ, Vavricka SR, Fried M, Schreiber S, Schuppler M, Rogler G.
Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans.
PLoS One. 2013;8(3)
Impact factor: 2.80
Citations: 103
107. Kelly OB, Mroz MS, Ward JB, Colliva C, **Scharl M**, Pellicciari R, Gilmer JF, Fallon PG, Hofmann AF, Roda A, Murray FE, Keely SJ.
Ursodeoxycholic acid attenuates colonic epithelial secretory function.
J Physiol. 2013 May 1;591(9):2307-18
Impact factor: 5.03
Citations: 13
108. Biedermann L, Mwinyi J, **Scharl M**, Frei P, Zeitz J, Kullak-Ublick GA, Vavricka SR, Fried M, Weber A, Humpf HU, Peschke S, Jetter A, Krammer G, Rogler G.
Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study.
J Crohns Colitis. 2013 May;7(4):271-9.
Impact factor: 5.81
Citations: 31
109. Spalinger MR, Lang S, Weber A, Frei P, Fried M, Rogler G, **Scharl M**.
Loss of protein tyrosine phosphatase nonreceptor type 22 regulates interferon- γ -induced signaling in human monocytes.
Gastroenterology. 2013 May;144(5):978-988.e10
Impact factor: 18.39
Citations: 26

110. **Scharl M**, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, Fried M, Weber A, Jehle E, Rühl A, Rogler G. *Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae.* Gut. 2013 Jan;62(1):63-72
Impact factor: 16.65
Citations: 28
111. Wojtal KA, Rogler G, **Scharl M**, Biedermann L, Frei P, Fried M, Weber A, Eloranta JJ, Kullak-Ublick GA, Vavricka SR. *Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.* PLoS One. 2012;7(8):e43361
Impact factor: 2.80
Citations: 20
112. Vavricka SR, Bentele N, **Scharl M**, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M; Swiss IBDnet and Swiss IBD Cohort Study Group. *Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).* Inflamm Bowel Dis. 2012 Aug;18(8):1523-30
Impact factor: 4.52
Citations: 21
113. **Scharl M**, Wojtal KA, Becker HM, Fischbeck A, Frei P, Arikkat J, Pesch T, Kellermeier S, Boone DL, Weber A, Loessner MJ, Vavricka SR, Fried M, McCole DF, Rogler G. *Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells.* Inflamm Bowel Dis. 2012 Jul;18(7):1287-302
Impact factor: 4.52
Citations: 34
114. **Scharl M**, Mwinyi J, Fischbeck A, Leucht K, Eloranta JJ, Arikkat J, Pesch T, Kellermeier S, Mair A, Kullak-Ublick GA, Truninger K, Noreen F, Regula J, Gaj P, Pittet V, Mueller C, Hofmann C, Fried M, McCole DF, Rogler G. *Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.* Inflamm Bowel Dis. 2012 May;18(5):900-12
Impact factor: 4.52
Citations: 26
115. **Scharl M**, Weber A, Fürst A, Farkas S, Jehle E, Pesch T, Kellermeier S, Fried M, Rogler G. *Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae.* Inflamm Bowel Dis. 2011 Sep;17(9):1907-16
Impact factor: 4.52
Citations: 15
116. Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, **Scharl M**, Seibold F, Straumann A, Michetti P; Swiss IBDnet. *Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.* Inflamm Bowel Dis. 2011 Jul;17(7):1530-9
Impact factor: 4.52
Citations: 15

117. **Scharl M**, Leucht K, Frey-Wagner I, Zeitz J, Hausmann M, Fischbeck A, Liebisch G, Kellermeier S, Pesch T, Arikkat J, Schmitz G, Fried M, Yildiz Y, Rogler G.
Knock-out of β -glucosidase 2 has no influence on dextran sulfate sodium-induced colitis.
Digestion. 2011;84(2):156-67
Impact factor: 2.08
Citations: 6
118. **Scharl M**, McCole DF, Weber A, Vavricka SR, Frei P, Kellermeier S, Pesch T, Fried M, Rogler G.
Protein tyrosine phosphatase N2 regulates TNF α -induced signalling and cytokine secretion in human intestinal epithelial cells.
Gut. 2011 Feb;60(2):189-97
Impact factor: 16.65
Citations: 24
119. Meier JK, **Scharl M**, Miller SN, Brenmoehl J, Hausmann M, Kellermeier S, Schölmerich J, Rogler G.
Specific differences in migratory function of myofibroblasts isolated from Crohn's disease fistulae and strictures.
Inflamm Bowel Dis. 2011 Jan;17(1):202-12
Impact factor: 4.52
Citations: 9
120. **Scharl M**, Hruz P, McCole DF.
Protein tyrosine phosphatase non-receptor Type 2 regulates IFN- γ -induced cytokine signaling in THP-1 monocytes.
Inflamm Bowel Dis. 2010 Dec;16(12):2055-64
Impact factor: 4.52
Citations: 20
121. **Scharl M**, Geisel S, Vavricka SR, Rogler G.
Dying in yoghurt: the number of living bacteria in probiotic yoghurt decreases under exposure to room temperature.
Digestion. 2011;83(1-2):13-7
Impact factor: 2.08
Citations: 1
122. **Scharl M**, Rudenko I, McCole DF.
Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion.
Am J Physiol Gastrointest Liver Physiol. 2010 Oct;299(4):G935-45
Impact factor: 3.46
Citations: 10
123. Hoda MR, **Scharl M**, Keely SJ, McCole DF, Barrett KE.
Apical leptin induces chloride secretion by intestinal epithelial cells and in a rat model of acute chemotherapy-induced colitis.
Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G714-21
Impact factor: 3.46
Citations: 5

124. **Scharl M**, Paul G, Weber A, Jung BC, Docherty MJ, Hausmann M, Rogler G, Barrett KE, McCole DF. *Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase n2.* Gastroenterology. 2009 Dec;137(6):2030-2040.e5
Impact factor: 18.39
Citations: 25
125. **Scharl M**, Paul G, Barrett KE, McCole DF. *AMP-activated protein kinase mediates the interferon-gamma-induced decrease in intestinal epithelial barrier function.* J Biol Chem. 2009 Oct 9;284(41):27952-63
Impact factor: 4.12
Citations: 21
126. Keating N, Mroz MS, **Scharl MM**, Marsh C, Ferguson G, Hofmann AF, Keely SJ. *Physiological concentrations of bile acids down-regulate agonist induced secretion in colonic epithelial cells.* J Cell Mol Med. 2009 Aug;13(8B):2293-303
Impact factor: 4.49
Citations: 12
127. Keely SJ, **Scharl MM**, Bertelsen LS, Hagey LR, Barrett KE, Hofmann AF. *Bile acid-induced secretion in polarized monolayers of T84 colonic epithelial cells: Structure-activity relationships.* Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G290-7.
Impact factor: 3.46
Citations: 18
128. Langmann T, Moehle C, Mauerer R, **Scharl M**, Liebisch G, Zahn A, Stremmel W, Schmitz G. *Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes.* Gastroenterology. 2004 Jul;127(1):26-40.
Impact factor: 18.39
Citations: 56

Anzahl Publikationen: 128

Kumulativer Impact Factor: 423.59

Summe der Zitationen: 1040

2. Übersichtsartikel

1. Butter M, Weiler S, Biedermann L, **Scharl M**, Rogler G, Bischoff-Ferrari HA, Misselwitz B. *Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people.* Maturitas. 2018 Apr;110:71-78.
Impact factor: 3.25
Citations: 0

2. Rogler G, Biedermann L, **Scharl M**.
New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways.
Swiss Med Wkly. 2018 Mar 22;148:w14599.
Impact factor: 1.65
Citations: 0

3. **Scharl M**, Rogler G, Biedermann L.
Fistulizing Crohn's Disease.
Clin Transl Gastroenterol. 2017 Jul 13;8(7):e106
Impact factor: 3.32
Citations: 2

4. **Scharl M**, Rogler G, Biedermann L
Anthocyanins, blueberries and curcuma: Effective therapeutic agents for bowel inflammations?
Schweizerische Zeitschrift für Ganzheitsmedizin, Volume 29, Issue 3, 1 June 2017, Pages 137-140
Impact factor: N/A
Citations: 0

5. Rogler G, Biedermann L, **Scharl M**.
Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor- α Therapy: Pathophysiology and Clinical Implications.
Dig Dis. 2017;35(1-2):5-12.
Impact factor: 1.77
Citations: 0

6. **Scharl M**, Bruckner RS, Rogler G.
The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease.
United European Gastroenterol J. 2016 Aug;4(4):506-14.
Impact factor: 3.67
Citations: 3

7. Siegmund B, Feakins RM, Barmias G, Ludvig JC, Teixeira FV, Rogler G, **Scharl M**.
Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease.
J Crohns Colitis. 2016 Apr;10(4):377-86
Impact factor: 5.81
Citations: 8

8. Spalinger MR, **Scharl M**.
The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis.
United European Gastroenterol J. 2016 Jun;4(3):325-32.
Impact factor: 3.67
Citations: 3

9. Spalinger MR, McCole DF, Rogler G, **Scharl M**.
Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease.
World J Gastroenterol. 2016 Jan 21;22(3):1034-44.
Impact factor: 3.36
Citations: 7

10. Vavricka SR, Schoepfer A, **Scharl M**, Lakatos PL, Navarini A, Rogler G.
Extraintestinal Manifestations of Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2015 Aug;21(8):1982-92
Impact factor: 4.52
Citations: 67

11. Spalinger MR, McCole DF, Rogler G, **Scharl M**.
Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation.
Inflamm Bowel Dis. 2015 Mar;21(3):645-55
Impact factor: 4.52
Citations: 8

12. **Scharl M**, Schaer D, Vallelian F.
[CME. Biologics in vasculitis].
Praxis (Bern 1994). 2015 Jan 2;104(1):7-16; quiz 15. Erratum in: Praxis (Bern 1994). 2015 Jan 28;104(3):116.
Impact factor: 0.06
Citations: 0

13. Gutermann IK, Niggemeier V, Zimmerli LU, Holzer BM, Battegay E, **Scharl M**.
Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines.
Medicine (Baltimore). 2015 Jan;94(1):e377
Impact factor: 1.80
Citations: 9

14. Vavricka SR, **Scharl M**, Gubler M, Rogler G.
Biologics for extraintestinal manifestations of IBD.
Curr Drug Targets. 2014;15(11):1064-73
Impact factor: 3.23
Citations: 11

15. **Scharl M**, Rogler G.
Pathophysiology of fistula formation in Crohn's disease.
World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):205-12
Impact factor: N/A
Citations: 0

16. Vavricka SR, Schoepfer AM, **Scharl M**, Rogler G.
Steroid use in Crohn's disease.
Drugs. 2014 Mar;74(3):313-24
Impact factor: 5.00
Citations: 4

17. **Scharl M**, Barthel C, Rogler G.
[Therapy of complicated Crohn's disease].
Praxis (Bern 1994). 2014 Mar 12;103(6):323-7
Impact factor: 0.06
Citations: 0

18. **Scharl M.**
[Therapy of chronic inflammatory bowel diseases: what comes next?].
Praxis (Bern 1994). 2014 Feb 12;103(4):185-6
Impact factor: 0.06
Citations: 0

19. **Scharl M, Biedermann L, Rogler G.**
Colitis-associated colorectal carcinoma: epidemiology, pathogenesis and early diagnosis].
Praxis (Bern 1994). 2014 Jan 29;103(3):149-54
Impact factor: 0.06
Citations: 0

20. Spalinger MR, Rogler G, **Scharl M.**
Crohn's disease: loss of tolerance or a disorder of autophagy?
Dig Dis. 2014;32(4):370-7
Impact factor: 1.77
Citations: 12

21. **Scharl M, Vavricka SR, Rogler G.**
Review: new anti-cytokines for IBD: what is in the pipeline?
Curr Drug Targets. 2013 Nov;14(12):1405-20
Impact factor: 3.23
Citations: 15

22. **Scharl M, Rogler G.**
Inflammatory bowel disease: dysfunction of autophagy?
Dig Dis. 2012;30 Suppl 3:12-9
Impact factor: 1.77
Citations: 22

23. **Scharl M, Rogler G.**
Inflammatory bowel disease pathogenesis: what is new?
Curr Opin Gastroenterol. 2012 Jul;28(4):301-9
Impact factor: 3.24
Citations: 38

24. **Scharl M, Rogler G.**
The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation.
Ann N Y Acad Sci. 2012 Jun;1257:93-102
Impact factor: 4.70
Citations: 5

25. **Scharl M, Rogler G.**
Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease.
Int J Inflam. 2010 Jun 29;2010:671258
Impact factor: 3.58
Citations: 0

26. **Scharl M**, Rogler G.
[Biologicals in gastroenterology: TNF-blockers].
Dtsch Med Wochenschr. 2010 Nov;135(45):2243-52
Impact factor: 0.08
Citations: 1

Anzahl Publikationen: 26

Kummulativer Impact Factor: 64.18

Summe der Zitationen: 215

3. Andere Publikationen

Buchbeiträge

1. **Scharl M**.
Rogler G, Herfarth H, Hibi T, Nielsen OH (eds):
Physiological Role of TNF in Mucosal Immunology: Regulation of T-Cell Function
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
Front Gastrointest Res. Basel, Karger, 2015, vol 34, pp 27-34
Citations: 0
2. **Scharl M**.
Rogler G, Herfarth H, Hibi T, Nielsen OH (eds):
Pathophysiological Role of TNF in Inflammatory Bowel Disease: TNF and Its Effect on Innate Immune Defense
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
Front Gastrointest Res. Basel, Karger, 2015, vol 34, pp 49-55
Citations: 1
3. Vavricka SR, **Scharl M**, Rogler G
Rogler G, Herfarth H, Hibi T, Nielsen OH (eds):
Pathophysiological Role of TNF in Inflammatory Bowel Disease: Anti-TNF therapy before surgery
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
Front Gastrointest Res. Basel, Karger, 2015, vol 34, pp 219-23
Citations: 0

Guidelines

1. Klionsky DJ et al.
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy. 2016;12(1):1-222
Impact factor: 8.59
Citations: 995
2. Klionsky DJ et al.
Guidelines for the use and interpretation of assays for monitoring autophagy.
Autophagy. 2012 Apr;8(4):445-544.
Impact factor: 8.59
Citations: 1882

Case reports

1. Russi L, **Scharl M**, Rogler G, Biedermann L.
The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.
Inflamm Intest Dis. 2017 Nov;2(2):131-138.
Impact factor: N/A
Citations: 0
2. **Scharl M**, Biedermann L.
A Symptomatic Coffee Bean: Acute Sigmoid Volvulus.
Case Rep Gastroenterol. 2017 May 22;11(2):348-351.
Impact factor: 0.97
Citations: 1
3. Misselwitz B, Epprecht J, Mertens J, Biedermann L, **Scharl M**, Haralambieva E, Lutterotti A, Weber KP, Müllhaupt B, Chaloupka K.
Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection.
Case Rep Gastroenterol. 2016 May 19;10(1):108-14
Impact factor: 0.97
Citations: 1
4. Vavricka SR, Greuter T, **Scharl M**, Mantzaris G, Shitrit AB, Filip R, Karmiris K, Thoeringer CK, Boldys H, Wewer AV, Yanai H, Flores C, Schmidt C, Kariv R, Rogler G, Rahier JF; ECCO CONFER investigators.
Cogan's Syndrome in Patients With Inflammatory Bowel Disease--A Case Series.
J Crohns Colitis. 2015 Oct;9(10):886-90
Impact factor: 5.81
Citations: 5
5. **Scharl M**, Stanek N, Kröger A, Bauerfeind P, Gubler C.
Successful treatment of a proximal esophageal rupture with a luminal sponge.
Endoscopy. 2015;47 Suppl 1 UCTN:E293-4
Impact factor: 5.44
Citations: 4

6. **Scharl M**, Bode B, Rushing E, Knuth A, Rordorf T.
Uncommon case of brain metastasis in a patient with a history of heavy smoking.
Curr Oncol. 2014 Oct;21(5):e728-31
Impact factor: 1.96
Citations: 1

7. Barthel C, Spalinger MR, Brunner J, Lang S, Fried M, Rogler G, **Scharl M**.
A distinct pattern of disease-associated single nucleotide polymorphisms in IBD risk genes in a family with Crohn's disease.
Eur J Gastroenterol Hepatol. 2014 Jul;26(7):803-6.
Impact factor: 1.96
Citations: 1

8. **Scharl M**, Frei P, Fried M, Rogler G, Vavricka SR.
Association between Cogan's syndrome and inflammatory bowel disease: a case series.
J Crohns Colitis. 2011 Feb;5(1):64-8.
Impact factor: 5.81
Citations: 8

Errata

1. Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, **Scharl M**, Aguzzi A, Oldridge DA, Maris JM, Rogler G.
Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
PLoS One. 2017 Jan 20;12(1):e0170851
Impact factor: 2.80
Citations: 0

2. **Scharl M**, Bruckner RS, Rogler G.
The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease.
United European Gastroenterol J. 2016 Dec;4(6):816.
Impact factor: 3.67
Citations: 3

3. Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Raselli T, Frey-Wagner I, Gutte PM, Grütter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G, **Scharl M**.
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
J Clin Invest. 2016 Nov 1;126(11):4388.
Impact factor: 12.78
Citations: 28

4. Siegmund B, Feakins RM, Barmias G, Ludvig JC, Teixeira FV, Rogler G, **Scharl M**.
Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease.
J Crohns Colitis. 2016 Jul;10(7):870.
Impact factor: 5.81
Citations: 8

5. Klionsky DJ et al.
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy. 2016;12(2):443. Selliez, Iban [corrected to Seilliez, Iban].
Impact factor: 8.59
Citations: 251

6. **Scharl M**, Schaer D, Vallelian F.
[CME. Biologics in vasculitis].
Praxis (Bern 1994). 2015 Jan 28;104(3):116.
Impact factor: 0.06
Citations: 0

Anzahl Publikationen: 19

Kumulativer Impact Factor: 73.81

Summe der Zitationen: 3189